Agenda

Thursday, January 21, 2010
7:00–8:00 a.m.	Continental Breakfast/Registration
Pretreatment Assessment
*Panelists:* Jean-Nicolas Vauthey, MD, Co-Chair Reid B. Adams, MD, Co-Chair Stephanie Wilson, MD Ahmed Kaseb, MD Paul Greig, MD
8:00–8:20	Staging of Hepatocellular Carcinoma Scott Helton, MD
8:20–8:30	*Discussion*
8:30–8:50	Optimizing Pretreatment Imaging of Hepatocellular Carcinoma Bachir Taouli, MD
8:50–9:00	*Discussion*
9:00–9:20	The Role of Portal Vein Embolization in Preparation for Hepatic Resection Eddie Abdalla, MD
9:20–9:30	*Discussion*
9:30–9:50	Defining Criteria for Resectability – Tumor Characteristics and Liver Function Timothy M. Pawlik, MD
9:50–10:00	*Discussion*
10:00–10:30	Break
Surgical Treatment
*Panelists:* William Jarnagin, MD, Co-Chair David M. Nagorney, MD, Co-Chair Elijah Dixon, MD Thomas A. Aloia, MD Alan W. Hemming, MD Myron Schwartz, MD
10:30–10:50	The Role of Thermal Ablation and Emerging Technologies in the Curative Therapy of Hepatocellular Carcinoma Steven Curley, MD
10:50–11:00	*Discussion*
11:00–11:20	Laparoscopic and Open Liver Resection for Hepatocellular Carcioma Michael D’Angelica, MD
11:20–11:30	*Discussion*
11:30–11:50	The Role of Bridge to Transplantation Therapy – Transarterial, Ablation, Resection, or Nothing? Charles B. Rosen, MD
11:50–Noon	*Discussion*
Noon–12:20	Milan and Extended Criteria for Liver Transplantation William C. Chapman, MD
12:20–12:30 p.m.	*Discussion*
12:30–1:30	Lunch (provided)
Combined Modality Treatment
*Panelists:* Alan P. Venook, MD, Co-Chair Roderich E. Schwarz, MD, PhD, Co-Chair Andrew X. Zhu, MD, PhD Melanie B. Thomas, MD Kelly W. Burak, MD
1:30–1:50	The Role of TACE and Emerging Therapies J. F. Geschwind, MD
1:50–2:00	*Discussion*
2:00–2:20	Systemic Therapy of Hepatocellular Carcinoma Ghassan K. Abou-Alfa, MD
2:20–2:30	*Discussion*
2:30–2:50	Yttrium-90 Microsphere Therapy Riad Salem, MD
2:50–3:00	*Discussion*
3:00–3:20	Photon and Proton Radiotherapy Sunil Krishnan, MD
3:20–3:30	*Discussion*
3:30	Adjourn

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

Agenda

Pretreatment Assessment

Surgical Treatment

Combined Modality Treatment